Influenza A virus (IAV) is an important human viral pathogen that is responsible for seasonal epidemics that cause substantial human morbidity and mortality and a considerable financial burden worldwide every year [1] [2] [3] . Although vaccines are available to prevent infections in humans, the haemagglutinin (HA) proteins of circulating viruses rapidly acquire mutations (known as antigenic drift), which prevent their recognition by the host immune system and necessitate replacement of the vaccine strains every 1-3 years. Antiviral compounds are available for prophylaxis and therapeutic treatment of severe IAV infections, but antiviral resistance is a continuing problem 4 . IAV pandemics can occur when viruses that contain HA or neuraminidase (NA) proteins, for which most humans lack pre-existing immunity, are transmitted to humans from reservoir species, including birds and pigs. As pre-existing immunity does not exist at the time of their emergence, pandemic viruses typically cause higher rates of infection and mortality among humans. The dangers that are posed by both seasonal and pandemic IAVs demand a complete understanding of how these viruses replicate, transmit and cause disease so that effective countermeasures can be developed.
. IAV pandemics can occur when viruses that contain HA or neuraminidase (NA) proteins, for which most humans lack pre-existing immunity, are transmitted to humans from reservoir species, including birds and pigs. As pre-existing immunity does not exist at the time of their emergence, pandemic viruses typically cause higher rates of infection and mortality among humans. The dangers that are posed by both seasonal and pandemic IAVs demand a complete understanding of how these viruses replicate, transmit and cause disease so that effective countermeasures can be developed.
At the end of virus replication, viral genetic material is packaged and released from infected cells so that additional cells or hosts can be infected. The IAV genome consists of eight unique segments of negative-sense viral RNA (vRNA), each of which is associated with multiple nucleoprotein (NP) molecules and a single, trimeric poly merase complex that comprises the PB1, PB2 and PA proteins. Collectively, each subunit of vRNA-NPpolymerase is referred to as a viral ribonucleoprotein (vRNP) complex. Following IAV entry into cells, vRNPs are released from endosomes and then transported into the nucleus, where they function as templates for genome transcription and replication; after the progeny vRNPs have been generated, they are transported out of the nucleus and to the plasma membrane for incorporation into newly forming virions (for a comprehensive review of the IAV life cycle, see  see BOX 1 for an overview of vRNP trafficking and function in infected cells).
Owing to the limited genetic coding capacity of IAVs (eight genome segments can encode up to 14 known viral proteins), these viruses depend on host proteins and pathways to mediate vRNP trafficking and to promote vRNP functions at all stages of the virus life cycle. In this Review, we summarize our current understanding of vRNP trafficking and functions in infected cells, emphasizing how vRNPs interface with host cell components and how the structure of vRNPs is related to their functions. In addition, we highlight questions that remain unanswered. Owing to space limitations, how the eight unique vRNPs are selectively assembled into infectious viruses, the interactions of vRNPs with the host innate immune system and the contribution of vRNP components to host species adaptation are not discussed in detail (for a review of these activities, see ; the selective packaging of influenza vRNP segments is summarized in BOX 2) . Given the centrality of vRNPs to every aspect of the IAV life cycle, a clearer 
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understanding of their fundamental roles during infection has enormous potential for revealing mechanisms of pathogenicity, for providing a basis for understanding host adaptation and for developing new methods to prevent or treat IAV disease.
vRNP structure Within the vRNP complex, NP binds stoichiometrically to vRNA (approximately one NP molecule per 24 nucleotides) with high affinity and without sequence specificity -via the phosphate backbone of RNA polymers -leaving the RNA bases accessible for pairing or genome duplication [9] [10] [11] . Higher-order double-stranded RNA structures seem to be present along the length of the vRNP, as RNA within vRNPs is partially sensitive to RNase V1 digestion 12 . The genomic ends of the vRNA do not associate with NP; rather, they fold back and base pair to form a double-stranded structure that is bound by the viral polymerase complex 13, 14 . By contrast, internal vRNA that is bound by NP forms a flexible, helical filament that is closed by a loop at the opposite pole to the genomic ends 11 . Two recent studies refined the structural models of the influenza vRNP complexes -derived either in native form from purified virions or from cells transfected with plasmids that encode the vRNP components -by using advanced electron microscopic analyses 15, 16 . These studies unambiguously demonstrated that the vRNP internal region comprises a twisted, antiparallel double helix of vRNA-NP complexes that is maintained by interactions between NP subunits. The same structures are detected within influenza virions 15 . A schematic representation of the vRNP structure is shown in FIG. 1. vRNP trafficking into the nucleus Influenza vRNP complexes within incoming virions are released from endosomes by the coordinated functions of the viral HA molecule and the M2 proton channel
. HA-mediated fusion between the viral and endosomal membranes provides an opening through which matrix-dissociated vRNPs can enter the cytoplasm. Meanwhile, M2 mediates vRNP dissociation from the virion matrix, which predominantly contains M1 protein, by acidifying the virion interior; this is necessary to make vRNPs competent for nuclear import 17, 18 . Cytoplasmic vRNPs that have dissociated from the M1 protein traffic into the nucleus using the classical importin-α-importin-β1 (IMPα-IMPβ1)-dependent nuclear import pathway (FIG. 2) . In this section, we describe the basic components of the IMPα-IMPβ1 pathway, the evidence that links it to IAV vRNP nuclear import and the interactions between the vRNPs and IMPα-IMPβ1 pathway components. A model for vRNP nuclear import is provide d in FIG. 2. IMPα-IMPβ1-mediated nuclear import. Proteins of less than 40 kDa can passively diffuse through the nuclear pore complex (NPC), whereas larger molecules and protein complexes, including vRNPs, must be transported by an active, energy-dependent process that involves the recognition of nuclear localization signals (NLSs) in cargo proteins (reviewed in REF. 19 ). The classical pathway of cellular protein nuclear import is mediated by IMPα adaptor proteins, which typically recognize basic (that is, arginine-and lysine-rich) NLSs, and in turn are recognized by the IMPβ transport receptor. The ternary IMPα-IMPβ-cargo complex subsequently traverses the NPC, and once inside the nucleus, IMPβ is dissociated by the activated form of the RAN GTPase (RAN-GTP), and IMPα-cargo complexes are released into the nucleoplasm. An additional dissociation step that involves the
Box 2 | Selective packaging of influenza vRNP segments
To preserve progeny virus infectivity, all eight unique viral ribonucleoprotein (vRNP) segments -representing each influenza virus gene -must be incorporated into a budding influenza virion. Historically, two mechanisms were proposed to explain how this could occur: either packaging proceeds by a selective process, in which only one copy of each vRNP segment is selected from a mixture of all vRNPs for incorporation into a single virion; or alternatively, random packaging occurs, in which vRNP incorporation is arbitrary and any subset of any of the eight vRNP segments could be packaged together. The selective packaging model predicts that only eight vRNP segments would be present in most (or all) influenza virions that are released from infected cells. By contrast, the random packaging model requires the incorporation of >8 vRNP segments into each virion to maintain infectivity rates consistent with experimental observations. An elegant electron microscopy study, which was carried out by Noda et al. 120 , provided compelling evidence in support of the selective packaging model, establishing that most influenza virions contain only eight vRNP segments, arranged in a '7 + 1' formation (that is, one central vRNP with seven other vRNPs forming a circle around it; a schematic representation of this arrangement is depicted in the figure, part a) , and that the individual segments within virions differ in length in a manner that is consistent with differences in gene segment sizes. A more recent study by Chou et al. 121 validated the observations made by Noda et al. by using single-molecule fluorescence in situ hybridization (smFISH) with probes specific for viral genomic RNA. Although the mechanism that controls how sets of eight vRNPs are selected from the cellular milieu for incorporation into virions is not well-clarified, each vRNA contains a packaging signal that encompasses terminal genomic regions (which are conserved across all vRNA segments) and internal coding regions (which are unique to each segment) [122] [123] [124] [125] [126] [127] [128] [129] [130] (packaging signals of each of the eight influenza A virus (IAV) vRNP segments, identified by deletion mapping studies in reporter constructs, are shown in the figure in part b; the lengths of the 3ʹ and 5ʹ coding regions (in nucleotides (nt)) that are required for efficient packaging of each segment are indicated). How these packaging signals mediate selective incorporation of their cognate vRNP remains an open question. However, the recent derivation of the three-dimensional structure of vRNP sets within IAV particles suggests that intra-virion vRNP-vRNP and vRNA-vRNA interactions may occur and that sets of vRNPs are incorporated into virus particles in a specific pattern 131 (not shown in the figure). Other recent evidence supports the possibility of direct RNA-RNA interactions between IAV vRNAs [132] [133] [134] [135] [136] . cellular CSE1L protein is required to liberate IMPα from the cargo molecules 20 . Following cargo release, IMPα and IMPβ are individually recycled back to the cytoplasm.
vRNPs and the IMPα-IMPβ1 pathway. By using NP trafficking to the nucleus as a proxy for vRNP nuclear import at very early times after infection, Martin and Helenius established that influenza vRNPs gain access to the nucleus via the NPC 21 . Studies with microinjected vRNPs further suggested that vRNPs use an active nuclear import process 22 . Additional studies with digitoni npermeabilized cells showed that influenza vRNA docks at the NPC only in the presence of IMPα, IMPβ and the viral NP, and also revealed that vRNA accumulation in the nucleus requires the RAN GTPase 23 . A small-molecule inhibitor of the IMPβ-RAN GTPase interaction (importazole) was more recently shown to impair vRNP nuclear transport 24 . These studies provide clear evidence that influenza vRNPs rely on the classical nuclear import pathway to enter the nucleus early in the virus life cycle.
Given that the classical nuclear import pathway mediates cargo transfer via recognition of NLS motifs, it is reasonable to predict that one or more of the vRNP protein components bears the NLS (or NLSs) that is required for vRNP nuclear import. All four vRNP protein components are reported to contain NLS motifs and enter the nucleus either alone (for NP and PB2) or in a complex (for PB1 and PA) [25] [26] [27] [28] [29] [30] [31] . However, although each virion-associated vRNP includes only a single trimeric polymerase complex, multiple NP subunits are present, which could provide several NLS motifs to promote nuclear import.
The NP protein encodes a non-classical (that is, not arginine-or lysine-rich) NLS ('ncNLS') within its first 13 amino acids 28, 29 , which binds to IMPα isoforms (IMPα1 and IMPα5) 29 , and is essential for both vRNP nuclear import in digitonin-permeabilized cells and for influenza virus replication 32 . NP also binds to IMPα3 and IMPα7 (REF. 33 ), although interactions with these isoforms are less well characterized. In both of the recently solved structural models of the influenza vRNP 15, 16 , the ncNLS motif is surface exposed, which suggests that it is available for interaction with IMPα adaptor proteins in vRNP complexes. Consistent with this observation, ultrastructural analysis of the surface availability of the ncNLS on purified vRNPs revealed multiple, periodically exposed motifs along the vRNP filament 34 . A second, classical, bipartite NLS (bNLS) has been identified in NP 30 , although its contribution to vRNP nuclear import has been questioned 32 . The bNLS was found to not be surface exposed on one of the vRNP structural models 16 , and experimental assessment suggested that there is only limited surface availability on vRNP structures 34 , which supports, at most, a limited role in vRNP nuclear import. Nonetheless, this substantial collection of evidence implicates NP as the vRNP component that is responsible for IMPα binding and vRNP nuclear import in early IAV infection and indicates that the ncNLS is most probably the dominant NLS motif.
Unanswered questions. Several interesting questions remain regarding vRNP trafficking into the nucleus during the early stage of IAV infection. First, although multiple NP ncNLS motifs are exposed on the surface of incoming vRNPs, it is not clear whether multiple IMPα-IMPβ1 complexes are associated with transporting vRNPs. In addition, as RAN-GTP is required to release vRNP complexes from docking at the nuclear membrane, it is presumed that IMPβ1 is dissociated from vRNP transport complexes as they enter the nucleus; however, whether IMPα is also dissociated remains to be determined. Some evidence suggests that IMPα can promote genome transcription and/or replication processes in addition to its activities in vRNP nuclear import (see below). Thus, if vRNPs recruit several IMPα proteins in the cytoplasm and maintain their association following nuclear import, this could provide an efficient means of rapidly establishing genome transcription. The potential contribution of the PB2 protein, which binds to multiple IMPα isoforms 33, 35 , should also be examined more closely.
Second, it is not clear whether vRNPs are transported into the nucleus as individual components, as bundles of eight vRNP complexes or as partially disrupted bundles that contain a subset of the eight vRNPs. A recent study Each influenza viral ribonucleoprotein (vRNP) consists of one single-stranded, negative-sense genomic RNA associated with multiple nucleoprotein (NP) monomers and a single trimeric polymerase complex (composed of PB1, PB2 and PA). The 5ʹ and 3ʹ vRNA ends are complementary and base pair to form a double-stranded structure, which is bound by the polymerase complex at one end of the vRNP filament. The internal vRNA region is organized into an antiparallel double helix, the formation of which is driven by contacts between NP monomers (known as the 'minor' groove), and a loop can be observed at the end of the filament opposite to that bound by the polymerase complex. Nature Reviews | Microbiology using single-molecule fluorescence in situ hybridization (smFISH) analysis to assess the distribution of two vRNA segments within the first hour of IAV infection suggested that these two vRNAs were only separated from each other after nuclear entry 24 . Although these data are compelling, additional studies are needed to clarify whether more than two vRNPs can undergo nuclear import together, and if so, how this affects the vRNP nuclear-import mechanism.
Generation and assembly of progeny vRNPs
Once in the nucleus, the primary roles of vRNPs are to transcribe viral mRNAs for the production of viral proteins and to replicate full-length complementary genomic RNA (cRNA) for amplification of vRNA and generation of progeny vRNPs
. In the following sections, we describe how vRNPs achieve genome transcription and replication and how host factors contribute to these processes. A model of primary transcription and genome replication is provided in FIG. 3 .
Primary genome transcription. After nuclear import, influenza vRNPs are transcribed to produce viral mRNAs (this is known as primary transcription) in a process that is independent of de novo viral protein synthesis 36 . Primary transcription is primer-dependent, and the primers that are used for this purpose, namely 7-methylguanosine-capped pre-mRNAs with 10-13 associated nucleotides, are obtained via 'cap-snatching' of cellular mRNAs by the viral polymerase complex [37] [38] [39] . Once the caps are acquired, transcripts are generated by replication from a vRNP template using the native polymerase complex of the vRNP (that is, in cis) 40 , and poly-A tails are produced by reiterative stuttering and copying of the poly-U sequence motif at the conserved 5ʹ end of the vRNA 41, 42 . With the recent availability of the structural model of vRNPs isolated from cells, a more specificalbeit speculative -model for primary transcription has been described 16 . Specifically, before initiation of primary transcription, vRNA termini are base paired and located adjacent to the PB1 active site. Then, after cap-snatching by the PB2 and PA proteins, the 3ʹ end of the vRNA is released from base pairing and transferred into the PB1 active site. Transcription proceeds as the PA carboxy-terminal domain feeds the vRNA strand to PB1 and, after the full-length gene has been transcribed, the 5ʹ terminus remains associated with PB1 to facilitate polymerase stuttering and the production of the poly-A tail.
Viral mRNA processing, transport and translation. After primary transcription, viral mRNAs are exported to the cytoplasm and translated by cellular ribosomes. The protein components of the vRNP complex are subsequently imported into the nucleus, where progeny vRNP complexes are assembled. As the processes associated with viral mRNA post-transcriptional modifications (for example, splicing), viral mRNA transport and viral protein translation are not directly relevant to the function, production or trafficking of vRNPs (aside from generating the raw components), they will not be described further here. Additional information can be found in other review articles [43] [44] [45] . Genome replication and RNP assembly. The replication of full-length genomic cRNA from vRNP complexes (and similarly, replication of full-length genomic vRNA from cRNA-containing RNP complexes (cRNPs)) contrasts strikingly with primary transcription. Genome replication requires newly translated NP and polymerase complex proteins to protect genomic RNA from degradation 46 , probably proceeds in the absence of an RNA primer owing to the presence of 5ʹ triphosphates at the 5ʹ ends of both vRNA and cRNA 43 and, most interestingly, can be initiated by soluble polymerase complexes in trans (that is, not by the polymerase complex that is resident in the RNP complex) 40, 47 . Support for the trans-genome replication model is provided by electron microscopy analyses of RNPs that have been purified from cells, which showed multiple branched RNP-like structures emanating from the full-length parental RNPs 16 . As the junction of these branches can be stained with antibodies that recognize the PB2 protein 16 , it is likely that they represent the activity of non-resident polymerase complexes in the process of generating progeny RNPs. Recently described RNP structural models further suggest that, for genome copying to occur in trans, interstrand connections between NP molecules, which form the minor groove of the RNP helical structure, may need to be locally disrupted 15 (although definitive evidence for this is currently lacking) and that RNA packaging into RNP complexes is initiated by binding of the polymerase complex (a polymerase complex that is different from the transcribing polymerase (or polymerases)) to the 5ʹ terminus of the nascent RNA molecule, which protects the RNA and also initiates the sequential addition of NP oligomers in the 5ʹ-to-3ʹ direction 15, 16 . How polymerase complexes, NP oligomers and the genomic RNA cooperate to achieve the final helical RNP structure remains an unanswered question.
Host factors in genome transcription, replication and RNP assembly. Several host factors have been shown to influence genome transcription, replication and RNP assembly but, in general, no unifying themes link these host factors together. Some (including RANBP5 (REF. 48 ), HSP70 (REF. 49 ) and HSP90 (REFS 50,51)) seem to indirectly promote influenza genome replication by enhancing the nuclear import and assembly of trimeric polymerase complexes, and they will therefore not be considered further here. Others that have established and direct roles in regulating RNP transcription, replication and/or vRNP assembly are discussed below.
Host factors that are involved in primary transcription of viral mRNAs include the RNA polymerase II (Pol II) complex and SFPQ. The viral polymerase complex interacts with actively transcribing Pol II 52 , presumably to acquire cellular mRNA caps via cap-snatching. However, the PB2 and PA proteins also promote Pol II degradation, which is an ability that is associated with increased IAV pathogenicity in mice 53 . SFPQ is a multi functional splicing factor that associates with several vRNP components 54, 55 and promotes polyadenylation of viral mRNA transcripts 54 . Progeny vRNP generation is promoted by the minichromosome maintenance (MCM) helicase complex, UAP56, the transcription-splicing coupling factor TAT-SF1, and FMR1. Five of the six components of the MCM complex, which is involved in cellular DNA replication, associate with the PA protein in isolation and with vRNPs in infected cells 56 . The MCM complex promotes the production of full-length viral RNA products, possibly by stabilizing interactions between nascent RNA and the viral polymerase complex 56 . Both UAP56, which is an RNA helicase, and TAT-SF1 interact with NP alone but not with NP that is associated with viral RNA, and both stimulate genomic RNA synthesis by promoting the formation of NP-RNA complexes [57] [58] [59] . The FMR1 protein is an RNA-binding protein that is required for efficient IAV replication in cells and mice 60 . FMR1 expression stimulates the production of all viral RNA species, transiently interacts with vRNP complexes and stimulates interactions between NP and polymerase complex proteins in the presence of vRNA, which suggests that it is involved in vRNP assembly 60 .
Other host factors, including CLE (also known as C14ORF166) and IMPα isoforms, have established roles in enhancing polymerase activity, but the specific mechanism (or mechanisms) are not well clarified. CLE, which is a positive modulator of Pol II activity 61 , interacts with several vRNP components, and its knockdown leads to impaired virus replication, which decreases both negative-and positive-sense viral RNA by an unknown mechanism 62 . The IMPα1 and IMPα7 cellular nuclear import receptors positively regulate viral polymerase activity in mammalian, but not in avian, cells independently of nuclear import functions 63, 64 . Although the specific mechanism is unknown, viruses that express PB2 proteins that have a mammalian-adapting amino acid (for example, lysine at residue 627), which substantially increases the replicative ability of the viral polymerase complex in mammalian, but not in avian, cells 65 , have impaired polymerase activity when IMPα1 or IMPα7 protein levels are reduced by use of RNA interference (RNAi), but there is no effect on the nuclear localization of the PB2 or NP proteins 63 . A similar reduction in polymerase activity was not observed for the avian PB2 variant (which has glutamic acid at residue 627) 63 , suggesting that IMPα proteins have an important role in the adaptation of IAV to different hosts. An additional study clearly demonstrated that IMPα7 contributes to the adaptation of avian viruses in mammals 33 . Another mammalianadapting PB2 mutation (asparagine at residue 701; known as '701N') indirectly enhances IAV polymerase activity in mammalian cells by increasing PB2 binding to IMPα1, thereby increasing PB2 nuclear import 35 . However, whether PB2 proteins that contain the 701N mutation have impaired polymerase activity relative to their avian counterpart (that is, proteins with aspartic acid at residue 701) in mammalian cells with reduced IMPα1 or IMPα7 expressio n is unknown.
Unanswered questions.
Although we have made substantial progress in understanding primary transcription and genome replication from vRNPs, one area that remains mostly unexplored is the specific contribution of host factors, particularly in light of observations that vRNP components are strongly implicated in the adaptation of IAV to mammalian hosts 8, [66] [67] [68] [69] . Several recent studies have revealed an abundance of interactions between host proteins and components of the vRNP complex [70] [71] [72] , and it will be interesting to fully establish how these factors contribute to the role of vRNPs in the virus life cycle. Another question is whether vRNPs associate with a specific nuclear site for primary transcription and genome replication activities. Given that vRNP targeting to a specific site could increase the likelihood of encountering host factors that are important for transcription and replication, this is a worthwhile area for future research.
Nuclear export of progeny vRNPs
In the late phase of infection, progeny vRNPs must be transported from the nucleus to plasma membrane sites of new virus formation. The first step in this process is nuclear export
. IAVs use the cellular CRM1 (also known as exportin-1)-dependent nuclear export pathway to mediate transport of vRNPs from the nucleus to the cytoplasm. In the following sections, we describe the basic components of the CRM1 pathway, how IAV usurps this pathway to preferentially export vRNPs, the interactions between vRNPs and CRM1 pathway components and how cellular kinase signalling may contribute to this process. These observations are summarized by the model of vRNP nuclear export shown in FIG. 4 .
The CRM1 nuclear export pathway. The cellular CRM1 protein is a nuclear export receptor that recognizes cargo proteins that have leucine-rich nuclear export signals (NESs). CRM1 binds to NES motifs in cargo proteins in the nucleus and, in association with the GTP-loaded RAN GTPase, transports cargo across the NPC. The RAN GTPase-activating protein (RANGAP), which is tethered to the cytosolic side of the NPC, hydrolyses RAN-GTP to RAN-GDP, and this facilitates dissociation of the complex and cargo release into the cytoplasm. RAN-GDP is subsequently transported back into the nucleus, and its GDP is exchanged for GTP by the chromatin-associated RAN guanylnucleotide exchange factor (RANGEF), RCC1, to enable another round of cargo protein nuclear export. vRNPs and the CRM1 export machinery. Influenza vRNPs are retained in the nucleus of infected cells in the presence of leptomycin B (LMB; a specific CRM1 inhibitor) [73] [74] [75] , which indicates that the CRM1 nuclear export pathway is essential for vRNP nuclear export. Interestingly, LMB treatment leads to vRNP accumulation at the nuclear periphery 73 , which suggests that this localization pattern is an intermediate step in vRNP nuclear export, preceding vRNP passage through the NPC. A subset of nuclear vRNPs are tightly bound to chromatin at the nuclear periphery of infected cells 76, 77 , and the amount of vRNPs in this region increases after LMB treatment 77 . These observations imply that vRNP association with chromatin could be the intermediate nuclear export step that was originally identified by examining vRNP localization after LMB treatment. Chromatin association would theoretically position vRNPs in close proximity to the RANGEF RCC1, which normally associates with chromatin; in support of this prediction, RCC1 and vRNPs form complexes in infected cells 77 . CRM1 is also recruited to chromatin during influenza virus infection and, compared with uninfected cells, complexes of CRM1-RAN-RCC1 are increased 77 . Given that CRM1-mediated nuclear export of cellular cargo decreases after infection despite the increased potential for CRM1 pathway activity 77 , it seems likely that IAV induces alterations to the host cell that result in sequestration of the CRM1 pathway machinery on chromatin at the nuclear periphery to exclude cellular cargo and provide preferential access to vRNPs.
Among the vRNP complex proteins, only NP has a known NES; however, infected cells that lack M1 or the nuclear export protein (NEP) cannot export NP from the nucleus 17, 76 , which indicates that these proteins are necessary for the vRNP nuclear export process. Evidence that links M1 and NEP to vRNP nuclear export is discussed below.
The M1 protein is directly implicated in the regulation of vRNP nuclear export, as cells that have been microinjected with M1-specific antibodies showed NP confinement to the nucleus during infection 17 and exogenous M1 expression in infected cells with impaired 'late' gene expression (late genes include HA, M1, M2 and NA and have delayed expression relative to the NP gene; their expression can be impaired with the H7 kinase inhibitor 78 ) rescued the ability of vRNPs to accumulate in the cytoplasm 76 . An NES motif has been reported for the M1 protein and, although mutation of this motif reduces the efficiency of vRNP nuclear export during infection, the same NES is not sensitive to LMB and thus probabaly does not interact with CRM1 (REF. 79 ). This indicates that the M1 NES motif is not directly responsible for linking vRNPs to the CRM1 export pathway. However, M1 and vRNPs must interact to promote vRNP nuclear export 80 , so it is possible that M1 functions as an intermediary between vRNPs and an additional CRM1-association factor. Alternatively, as vRNPs are tightly associated with chromatin 76, 77 and M1 has also been associated with chromatin proteins 77, 81 , another (not necessarily exclusive) possibility is that M1 binding is required to release vRNPs from chromatin to enable nuclear export progression. In addition to promoting vRNP nuclear export, the association between M1 and vRNPs prevents nuclear re-import of vRNPs 82 , potentially because M1 shields vRNP NLS motifs from recognition by nuclear import adaptor proteins; however, associations between M1 and cytoplasmic vRNPs are not well established, so the precise mechanism of M1-impaired vRNP nuclear re-import requires further investigation.
The influenza NEP protein (or NS2) also has an important role in vRNP nuclear export. Similarly to M1, when NEP-specific antibodies were microinjected into the nuclei of infected cells, NP was retained in the nuclei, which suggests that vRNP nuclear export was impaired when NEP protein functions were blocked 83 . Furthermore, infectious influenza viruses that do not express NEP could not be recovered by reverse genetics, which indicates that NEP is essential to the IAV life cycle. This was attributed to a defect in vRNP nuclear export as NP was restricted to the nucleus in cells that were infected with the recovered, NEP-deficient viruslike particles 84 . NEP interacts directly with CRM1 via two amino-terminal hydrophobic NES motifs, which are both sensitive to LMB and sufficient to transfer nuclear export activity to nuclear-constrained proteins [83] [84] [85] . Mutation of either NES motif in isolation does not ablate NEP binding to CRM1 (REFS 84, 85) , whereas mutation of both motifs in parallel results in an almost complete loss of the NEP-CRM1 interaction 85 . Mutations in NES1 inhibit virus recovery by reverse genetics and strongly impede vRNP nuclear export 84 , whereas mutations in NES2 do not abolish virus recovery but severely impair viral growth kinetics and reduce the rate of vRNP nuclear export in infected cells 85 . Although these observations provide strong evidence of a role for NEP in vRNP nuclear export, no direct interaction between full-length NEP and the vRNP complex has been established 83, [86] [87] [88] [89] . However, as NEP can interact directly with the M1 protein 86, 90 , which in turn interacts with vRNPs 80 , a 'daisy-chain model' for influenza vRNP nuclear export has been proposed, whereby NEP functions as an adaptor between the CRM1 nuclear export pathway and M1-vRNP complexes (FIG. 4) . Recent data suggest that a more refined model -in which NEP simultaneously interacts with M1, the PB1 subunit of the vRNP-associated polymerase complex and the CRM1 nuclear export receptor 89 -may be necessary to explain the mechanism of vRNP nuclear export, but further work is needed to clarify this process. In addition, whether NEP remains associated with vRNP complexes that have been transported to the cytoplasm is currently unknown.
The NP protein can undergo nuclear export in the absence of other viral proteins 28, 82 and encodes residues that are involved in nuclear export within its N-terminal 38 amino acids 28 . A recent study suggested that other NP NES motifs may exist 91 . In addition, NP binds directly to CRM1 in vitro 74 . These observations imply that the NP protein could mediate vRNP nuclear export via a direct interaction with CRM1; however, the contribution of specific NP NES motifs to vRNP nuclear export has never been established in the context of infected cells or with isolated vRNP complexes. Accordingly, the role of NP in vRNP nuclear export remains unclear.
Cellular kinases and vRNP nuclear export. Cellular protein kinase activity may affect vRNP nuclear export. Specifically, vRNP nuclear export is impaired in infected cells that have been treated with a protein kinase C inhibitor 76 , a RAF-MEK-ERK mitogen-activated protein kinase (MAPK) inhibitor 92 , a receptor tyrosine kinase inhibitor 93 and a serum-and glucocorticoidregulated kinase 1 inhibitor 94 , which suggests that phosphorylation of viral and/or cellular factors is required for this process. Interestingly, vRNP nuclear export can be enhanced by viral HA-mediated activation of the cellular RAF-MEK-ERK MAPK signalling pathway, which occurs when HA is expressed at the plasma membrane 95, 96 . This suggests that there is an indirect role for HA in promoting vRNP nuclear export. In addition, as HA is abundant in virus particles and vRNPs must come into contact with HA at plasma membrane sites to form progeny virions, HA-mediated RAF-MEK-ERK induction could function as a signal to activate vRNP nuclear export when the budding sites are 'ready' (that is, when HA is present). Although the specific phosphorylation events and the kinases that are involved in promoting vRNP nuclear export have not yet been defined, it is notable that viral proteins with direct roles in the vRNP nuclear export process (such as NP, M1 and NEP) all exist as phosphoproteins in infected cells [97] [98] [99] [100] [101] . Unanswered questions. Although considerable effort has been applied towards a better understanding of the vRNP nuclear export mechanism, questions still remain.
First, the recent identification of chromatin targeting as a mechanism to facilitate vRNP access to the nuclear export machinery is interesting, and opens new avenues for research. It will be important to determine how this sequestration occurs and the extent to which it affects host nucleocytoplasmic trafficking.
Second, although the daisy chain hypothesis can explain how influenza vRNPs are transported to the cytoplasm, tangible evidence to support complex formation in infected cells is lacking, despite being a requirement to validate this proposed mechanism. Furthermore, it is unknown whether vRNP complexes are exported from the nucleus as individual vRNP components or as complexes of multiple vRNPs, although a few studies seem to support the former possibility 24, 102 . As this information could provide insights into the mechanism of incorporation of the full set of eight unique vRNPs into the assembling virions, further clarification of the nature of the transport complex is necessary.
Third, although many reports indicate that phosphorylation of some viral or cellular target (or targets) may be crucial for vRNP nuclear export, there are essentially no available data to explain this phenomenon. Additional studies are needed to identify the viral or cellular target (or targets) involved.
vRNP transport through the cytoplasm Nuclear export constitutes only part of the passage of vRNPs to the IAV budding site. vRNPs must also navigate through a dense matrix of cytoplasmic structures to reach the plasma membrane
. Combined with the observation that IAV progeny viruses bud from discrete plasma membrane sites 103 , it is logical to predict that vRNP cytoplasmic transport is organized rather than random. Indeed, a recent focus on this phase of the IAV life cycle has shown that vRNPs are transported on microtubule networks, in association with RAB11-positiv e recycling endosomes.
Cytoskeletal networks. Three types of cytoskeletal filaments are found in distinct networks in eukaryotic cells: actin microfilaments, microtubules and intermediate filaments. All three contribute to the structure, stability and integrity of the cell, but cargo-mediated transport occurs only along microfilaments and microtubules. Myosin motors transport cargo on actin filaments, which are concentrated directly under the plasma membrane. Alternatively, kinesin and dynein motors transport cargo on microtubules, which are nucleated at the microtubule organizing centre (MTOC) and typically emanate from the centre of the cell to its periphery.
Microtubules and vRNPs. Soon after nuclear export, vRNPs accumulate near the MTOC 104, 105 , which is located immediately adjacent to the nucleus. Later, they are aligned with microtubule networks en route to the plasma membrane 104, 106 . Although these observations are suggestive of the use of microtubules in the cytoplasmic transport of vRNPs, several lines of evidence provide more direct support for this concept: live-cell imaging studies using fluorescently tagged vRNP components demonstrate vRNP movement along microtubule tracks 106 , which is characterized by intermittent, saltatory motions [105] [106] [107] (this type of motion is well-established for microtubule-mediated cargo 108, 109 ); cells that are treated with microtubule depolymerizing agents have altered vRNP distribution and reduced microtubule-like movement 104, 105, 107 ; and IAV growth is reduced in cells that are treated with a microtubule-depolymerizing agent 104 . Overall, these findings strongly implicate microtubule networks in vRNP cytoplasmic transport, although no studies have yet addressed whether a specific motor complex is involved.
RAB11 and vRNPs.
Membrane-bound vesicles are a common microtubule cargo in eukaryotic cells. Under normal physiological conditions, early and late endosomes and lysosomes are transported predominantly inwards, towards the centre of the cell, whereas secretory vesicles that are derived from the Golgi complex, and vesicles of the recycling endosome system, are transported outwards, towards the cell periphery. Both vRNA and vRNPs colocalize extensively with RAB11-positive recycling endosomes in infected cells 24,105-107,110 -initially concentrated at the MTOC immediately after nuclear export, and later localized throughout the cytoplasm and near the plasma membrane -which suggests that vRNPs 'piggy-back' on RAB11 vesicles for transport through the cytoplasm. At the end of the IAV life cycle, vRNPs seem to transfer from RAB11-positive vesicles to the plasma membrane 110 , which suggests that there is a mechanism to extract vRNPs from RAB11 vesicle surfaces for incorporation into budding virions. The lack of RAB11 detection in influenza virus particles 111 reinforces this premise. In support of a specific role for RAB11 in mediating vRNP cytoplasmic transport (as opposed to 'guilt by colocalization'), RAB11 protein knockdown and exogenous overexpression of a dominant-negative RAB11 mutant protein both impaired the association of vRNPs with RAB11-positive vesicles, disrupted accumulation of vRNPs at the plasma membrane and sharply reduced the output of infectious progeny virus 106, 110 . In infected cells, RAB11 forms a complex with all vRNP protein components and with vRNA, but when complexes are treated with RNase, only the association with the polymerase complex proteins (PB1, PB2 and PA) is maintained 106 . Furthermore, direct binding is observed only between RAB11 and the PB2 protein of the polymerase complex 105 . As a single polymerase trimer is associated with each vRNP complex -localized with the base-paired genomic ends -these observations predict that the RAB11 GTPase recruits vRNPs to the recycling endosome membrane in a head-to-tail orientation, with polymerase-bound genomic ends attached to the membrane and the looped ends facing away from the membrane. In addition to providing a convenient mechanism for cytoplasmic transport, RAB11-positive vesicles may function as a platform for concentrating vRNPs (thereby reducing their diffusion) before virus assembly and budding, which may promote interactions that are necessary for creating supramolecular complexes of vRNP; however, this hypothesis has not been experimentally tested.
Other host factors and vRNP cytoplasmic transport. Several additional host proteins have been ascribed potential functions in the cytoplasmic transport of vRNP complexes. Two components of host RNP complexes that regulate translation of cellular mRNAs -YB-1 and STAU1 -are associated with influenza vRNPs during late-stage infection 112, 113 . The YB-1 protein translocates to the nucleus in infected cells, where it localizes with vRNA and can later be found in complexes with α-tubulin, RAB11 and vRNP components in the cytoplasm 112 , which suggests that it undergoes nuclear export in complex with vRNPs. Overexpression of YB-1 also stimulates the production of infectious progeny viruses in a RAB11-dependent manner 112 . On the basis of these observations, it has been suggested that YB-1 facilitates the delivery of vRNPs to RAB11 endosomes at the MTOC following nuclear export, but direct evidence in support of this hypothesis is lacking. The role of STAU1 is less clear, although this factor is thought to promote a late stage of the influenza virus life cycle, as STAU1 knockdown by RNAi does not impair viral protein expression or vRNP nuclear export 113 . The HIV rev-binding protein (HRB), which is a host endosomal protein 114, 115 and an NEP interaction partner 83 , is essential for efficient influenza virus replication and can be visualized in association with influenza vRNPs at the microtubule organizing centre (MTOC) after vRNP nuclear export 116 . RNAi-mediated knockdown of HRB results in the retention of vRNPs in the perinuclear region, which suggests that HRB has a role in the transport of vRNPs from the MTOC to the plasma membrane.
Viral proteins and vRNP recruitment to the budding site.
As noted above, RAB11 does not seem to be incorporated into budding virus particles, which implies that there is another mechanism for vRNP recruitment at the budding site
. Several reports have suggested that the M2 protein is required for this process [117] [118] [119] and that it occurs via a direct interaction between M1 and the M2 cytoplasmic tail 119 . As already noted, the M1 protein is required for vRNP nuclear export 17, 76 and prevents vRNP nuclear re-import in late-stage infection, which suggests that M1 remains associated with vRNPs that have been transported to the cytoplasm. However, association of M1 with vRNPs on RAB11 vesicles has not been demonstrated. Nonetheless, these observations suggest that M1-coated vRNPs are recruited by the M2-M1 interaction when RAB11 has delivered vRNPs to the plasma membrane.
Open questions. Recent data have unambiguously implicated microtubules and RAB11 in vRNP transport through the cytoplasm. However, how the vRNPs are recruited to the RAB11 vesicles, how these vesicles are attached to microtubules and the signals that promote RAB11 vesicle trafficking to the cellular periphery remain open questions.
Perspectives and future directions
The multidimensional trafficking and functions of vRNP complexes are essential to the IAV life cycle and, although complex, merit the considerable effort that has been applied towards their improved understanding. However, much remains to be learned, and additional work is required to elucidate the full spectrum of vRNP activities in infected cells. Key open questions have already been described throughout this Review. Below, we elaborate on the most important of these questions, emphasizing crucial experimental approaches that are required for generating the most comprehensive model of vRNP function during IAV infection.
An important and unsolved problem in IAV biology is the mechanism by which a complete set of eight vRNP segments is selected and assembled for incorporation into progeny virions. This process is likely to involve: aspects of vRNP structure; the accessibility of vRNAs within vRNP structures, which could enable interactions with other vRNAs, proteins or cellular RNA species; inter-segment interactions between unique vRNPs (driven either by vRNA-vRNA or by protein-based associations) (see BOX 2 for additional details); and intracellular trafficking mechanisms that promote interactions between vRNPs. A more advanced understanding of these processes will require the use of cutting-edge technologies in structural analysis (such as crystallization of native RNP structures), high-resolution electron microscopy, innovative light microscopy approaches (such as super-resolution methods in combination with live-cell imaging and/or smFISH) and the application of these technologies to realistic models of IAV infection (for example, primary cells or tissue explants). Increased knowledge about the mechanism of vRNP assembly will provide insights into how IAVs undergo reassortment (and cause pandemics) and, in addition, may open novel channels for antiviral development, including the development of molecules that interfere with vRNP-vRNP interactions. Thus, resolving the mechanism of vRNP assembly should be pursued in earnest.
Another major gap in knowledge is the lack of a comprehensive understanding of the sizeable network of host proteins that interact with the IAV polymerase complex and/or vRNPs and how this network contributes to vRNP activities. There is an even greater paucity of information about how avian and mammalian vRNP components differentially interact with this host protein network and whether putative differences could affect inter-species virus transmission. The continued use of RNAi and other mechanisms to interfere with the expression or activity of specific host factors within this network will be essential for defining the role of a particular factor in regulating vRNP functions and, when possible, studies should be extended into animal models of IAV disease, including knockout mice. In addition, computational strategies could be more effectively used in combination with available and new high-throughput data sets (including protein-protein interaction data, genome-wide knockdown studies and 'omics' analyses of infected cells or tissues) to identify the host factor candidates that have the strongest regulatory influence over the virus life cycle and/or inter-species transmission.
As we have already described, there is a crucial need for the development of novel antiviral strategies for the treatment of severe influenza virus disease in humans. Two classes of antiviral drugs are currently available: adamantanes, which impair viral M2 ion channel activity; and NA inhibitors, such as oseltamivir and zanamivir. However, owing to the remarkable propensity of influenza viruses to adapt under selective pressure, use of these compounds has resulted in the widespread emergence of virus strains that are resistant to one or both inhibitor classes 4 . An alternative antiviral development strategy -targeting an essential host factor (rather than a viral protein) -may reduce the emergence of resistant variants as it may be difficult for the virus to bypass the use of such a factor. As vRNPs are central to the IAV life cycle and depend on host factors for their functions, knowledge gained from a deeper understanding of vRNP-host machinery interactions could yield unique strategies for host-targeted antiviral development and this knowledge must therefore be further expanded.
Altogether, the combination of extensive previous work and future efforts aimed at clarifying mechanisms that regulate vRNP functions in IAV-infected cells will not only improve our basic scientific knowledge but may also reveal novel mechanisms of IAV pathogenicity and adaptation to mammalian hosts and, furthermore, could lead to the identification of novel (viral or cellular) druggable targets that might be exploited to prevent or treat IAV disease.
